-
Product Insights
New![]()
Net Present Value Model: Celldex Therapeutics Inc’s Barzolvolimab
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. Celldex Therapeutics Inc's Barzolvolimab Drug Details: Barzolvolimab (CDX-0159 is under development for the treatment of chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU), eosinophilic...
-
Company Profile
![]()
Celldex Therapeutics Inc – Company Profile
Celldex Therapeutics Inc (Celldex) is a bio-pharmaceutical company that discovers, develops, and commercializes targeted immunotherapy and other biologics for the treatment of various types of cancers. The company’s developmental pipeline comprises therapeutic antibodies, antibody drug conjugates (ADCs), protein-based therapeutics, immune system modulators and vaccine for unmet medical needs. Its key products in development include CDX-1140, CDX-527, CDX-0159. Celldex’s products find application in the treatment of various indications such as brain cancer, triple negative breast cancer, lymphoma/leukemia, melanoma, and renal cell...
Add to Basket -
Product Insights
New![]()
Net Present Value Model: Bayer AG’s Elinzanetant
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CDX-585 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CDX-585 in Solid Tumor Drug Details: CDX-585 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AL-1211 in Gaucher Disease Type I
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AL-1211 in Gaucher Disease Type I Drug Details: AL-1 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IO-202 in Refractory Acute Myeloid Leukemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.IO-202 in Refractory Acute Myeloid Leukemia Drug Details:IO-202 is under development for the treatment of relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Barzolvolimab in Eosinophilic Esophagitis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Barzolvolimab in Eosinophilic Esophagitis Drug Details: Barzolvolimab (CDX-0159 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Barzolvolimab in Prurigo
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Barzolvolimab in Prurigo Drug Details: Barzolvolimab (CDX-0159 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BA-3071 in Melanoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BA-3071 in Melanoma Drug Details:BA-3071 is under development for non-small cell lung cancer, colon adenocarcinoma, small...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BA-3071 in Renal Cell Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BA-3071 in Renal Cell Carcinoma Drug Details:BA-3071 is under development for non-small cell lung cancer, colon...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DCSZ-11 in Head And Neck Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.DCSZ-11 in Head And Neck Cancer Drug Details:DCSZ-11 is under development for the treatment of metastatic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CPT-31 in Human Immunodeficiency Virus (HIV) Infections (AIDS)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CPT-31 in Human Immunodeficiency Virus (HIV) Infections (AIDS) Drug Details:CPT-31 (CPT31-LA) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MS-553 in Relapsed Chronic Lymphocytic Leukemia (CLL)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MS-553 in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details:MS-553 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ascorbic Acid in Bronchiolitis Obliterans
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ascorbic Acid in Bronchiolitis Obliterans Drug Details: Ascorbic acid is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Elzovantinib in Metastatic Colorectal Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Elzovantinib in Metastatic Colorectal Cancer Drug Details: Elzovantinib (TPX-0022) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – STT-003 in Bile Duct Cancer (Cholangiocarcinoma)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. STT-003 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: STT-003 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Garadacimab in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Garadacimab in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Drug Details:Garadacimab (CSL-312) is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PYX-201 in Kidney Cancer (Renal Cell Cancer)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PYX-201 in Kidney Cancer (Renal Cell Cancer)Drug Details:PYX-201 is under development for the treatment of non-small...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AGENT-797 in Rectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AGENT-797 in Rectal Cancer Drug Details: AGENT-797 is under development for the treatment of moderate...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CDX-301 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CDX-301 in Non-Small Cell Lung Cancer Drug Details: CDX-301 is under development for the treatment...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.